文献速递鼻科

评估慢性鼻窦炎患者报告结局指标的反应性

Evaluating metrics of responsiveness using patient-reported outcome measures in chronic rhinosinusitis.
PubMed 文献 · Int Forum Allergy Rhinol · 2016-11-07

本研究比较慢性鼻窦炎(CRS)患者报告结局指标(PROM)的反应性。药物治疗组143例和鼻内镜手术组123例在基线和3个月时完成SNOT-22、EPOS VAS和PROMIS-29。结果显示CRS特异性PROM比通用健康指标更敏感,且现有PROM对手术的反应性大于药物治疗。

要点

  • CRS特异性PROM(VAS、SNOT-22)在药物和手术治疗后均比PROMIS-29通用健康领域更敏感。
  • SNOT-22包含可能降低其整体反应性的条目。
  • 现有PROM对鼻内镜手术的反应性大于药物治疗。

核心结论

  • 对于药物和手术治疗患者,CRS特异性PROM对治疗后临床变化的反应性均高于通用健康指标。
  • SNOT-22包含可能降低其整体反应性的条目。
  • 现有PROM对鼻内镜手术的反应性大于药物治疗。

研究设计与样本

  • 本研究为比较PROM反应性的研究,纳入接受药物治疗(MT;n=143)或药物治疗失败后接受鼻内镜手术(ESS;n=123)的成人CRS患者。
  • 患者在基线和治疗后3个月完成22项鼻腔鼻窦结局测试(SNOT-22)、欧洲鼻窦炎立场声明(EPOS)视觉模拟量表(VAS)和29项患者报告结局测量信息系统(PROMIS-29)。
  • 使用Cohen's d和配对t统计量评估各指标的反应性。

主要发现

  • MT组52例(36.4%)和ESS组42例(34.1%)完成了基线和3个月问卷。
  • 有和无3个月数据的受试者在基线人口学、VAS评分和SNOT-22评分方面相似(p > 0.05)。
  • MT患者中,CRS特异性指标VAS(d = -0.58,p < 0.01;t = -1.81,p > 0.05)和SNOT-22(d = -0.70,p < 0.01;t = -3.29,p < 0.05)比PROMIS-29通用健康领域(Cohen's d的p > 0.05)更敏感。
  • ESS患者中,VAS(d = -1.97;t = -9.63,均p < 0.01)和SNOT-22(d = -1.56;t = -9.99,均p < 0.01)同样更敏感,但PROMIS-29的疲劳(d = -0.82,p = 0.01;t = -4.63,p < 0.01)、睡眠障碍(d = -0.83;t = -3.77,均p < 0.01)和疼痛强度(d = -1.0;t = -5.67,均p < 0.01)领域的变化显著。
  • 术后SNOT-22所有22个条目均显著不同,而MT后仅8个条目持续敏感。

关键数值与推荐

  • MT组:VAS d = -0.58(p < 0.01),t = -1.81(p > 0.05);SNOT-22 d = -0.70(p < 0.01),t = -3.29(p < 0.05)。
  • ESS组:VAS d = -1.97,t = -9.63(均p < 0.01);SNOT-22 d = -1.56,t = -9.99(均p < 0.01)。
  • ESS组PROMIS-29:疲劳 d = -0.82(p = 0.01),t = -4.63(p < 0.01);睡眠障碍 d = -0.83,t = -3.77(均p < 0.01);疼痛强度 d = -1.0,t = -5.67(均p < 0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Responsiveness, or sensitivity to clinical change, is important when selecting patient-reported outcome measures (PROMs) for research and clinical applications. This study compares responsiveness of PROMs used in chronic rhinosinusitis (CRS) to inform the future development of a highly responsive instrument that accurately portrays CRS patients' symptom experiences. METHODS: Adult CRS patients initiating medical therapy (MT; n = 143) or undergoing endoscopic sinus surgery after failing MT (ESS; n = 123) completed the 22-item Sino-Nasal Outcome Test (SNOT-22), European Position Statement on Rhinosinusitis (EPOS) visual analog scale (VAS), and 29-item Patient-Reported Outcomes Measurement Information System (PROMIS-29) at baseline and 3 months after treatment. Cohen's d and paired t statistics were used to evaluate the responsiveness of each measure. RESULTS: Fifty-two (36.4%) subjects and 42 (34.1%) subjects in the MT and ESS groups, respectively, completed baseline and 3-month questionnaires. Subjects with and without 3-month data were similar with respect to baseline demographics, VAS scores, and SNOT-22 scores (p > 0.05). In MT patients, CRS-specific measures, like VAS (d = -0.58, p < 0.01; t = -1.81, p > 0.05) and SNOT-22 (d = -0.70, p < 0.01; t = -3.29, p < 0.05) scores, were more responsive than PROMIS-29 general health domains (p > 0.05 for Cohen's d). In ESS patients, VAS (d = -1.97; t = -9.63, both p < 0.01) and SNOT-22 (d = -1.56; t = -9.99, both p < 0.01) scores were similarly more responsive, although changes in PROMIS-29 domains of Fatigue (d = -0.82, p = 0.01; t = -4.63, p < 0.01), Sleep Disturbance (d = -0.83; t = -3.77, both p < 0.01), and Pain Intensity (d = -1.0; t = -5.67, both p < 0.01) were significant. All 22 individual SNOT-22 items differed significantly after surgery, whereas only 8 items were consistently responsive after MT. CONCLUSIONS: For both MT and ESS patients, CRS-specific PROMs are more responsive to posttreatment clinical changes than general health measures. Still, the SNOT-22 contains items that likely decrease its overall responsiveness. Our findings also indicate that existing PROMs had a greater response to ESS than MT.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Lidder AK, Detwiller KY, Price CP, et al. Evaluating metrics of responsiveness using patient-reported outcome measures in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2016. PMID: 28177596. doi:10.1002/alr.21866

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。